GH Research PLC (“GH Research” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The Company’s initial focus is on developing novel and proprietary 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. The Company’s portfolio currently includes GH001, a proprietary inhalable 5-MeODMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, a proprietary injectable 5-MeO-DMT product candidate. The Company’s lead program, GH001, is currently in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD.